Home › Atopic Dermatitis (Eczema) › Maryland
Atopic Dermatitis (Eczema) clinical trials in Maryland
16 studies for Atopic Dermatitis (Eczema) are looking for participants at sites in Maryland.
Cities in Maryland
Natural History and Genetics of Food Allergy and Related Conditions
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
1 Day – 99 Years · All sexes · Updated Oct 2, 2026 · NCT02504853Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 12 to 120 · All sexes · Updated Oct 2, 2026 · NCT07262983Effects of Treatments on Atopic Dermatitis
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2Healthy volunteers welcome
Ages 2 to 50 · All sexes · Updated Sep 28, 2026 · NCT01631617A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Rockville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07003425Metabolic Profiling of Immune Responses in Immune-mediated Diseases
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Sep 22, 2026 · NCT04864886Studies of Skin Microbes in Healthy People and in People With Skin Conditions
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 100 · All sexes · Updated Sep 16, 2026 · NCT00605878Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- U.S. Dermatology Partners Rockville, Rockville
RecruitingObservational study
Ages 12 to 89 · All sexes · Updated Sep 15, 2026 · NCT07645820A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Chesapeake Clinical Research, Inc, Pasadena
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Aug 28, 2026 · NCT07599813Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 3 to 21 · All sexes · Updated Aug 26, 2026 · NCT03835767Cardamom and Topical Roseomonas in Atopic Dermatitis
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 2 to 100 · All sexes · Updated Aug 13, 2026 · NCT06096857A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Maryland Allergy & Asthma Center /ID# 268032, Lanham
RecruitingPhase 3
Ages 2 to 11 · All sexes · Updated Aug 6, 2026 · NCT06461897A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 3 to 100 · All sexes · Updated Jul 17, 2026 · NCT06732414A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Maryland Laser Skin and Vein, Hunt Valley
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 4, 2026 · NCT05995964Dupilumab De-escalation in Pediatric Atopic Dermatitis
- Johns Hopkins Univerisity, Baltimore
RecruitingPhase 4
Ages 1 to 17 · All sexes · Updated Apr 20, 2026 · NCT06116526Registry for Systemic Eczema Treatments
- Johns Hopkins University, Baltimore
RecruitingObservational study
Ages 1 to 26 · All sexes · Updated Apr 7, 2026 · NCT06136767Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7098, Columbia
- Galderma Investigational Site 8012, Glenn Dale
- Galderma Investigational Site 7068, Rockville
RecruitingObservational study
Ages 12 and older · All sexes · Updated Mar 13, 2026 · NCT06988605From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.